Use of B-type natriuretic peptide outside of the emergency department

International Journal of Cardiology

Volumn 127, Issue 1, 2008, Pages 5-16

  Maeder, Micha T ^a   Mueller, Christian ^a   Pfisterer, Matthias E ^a   Buser, Peter T ^a   Brunner La Rocca, Hans P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

B type natriuretic peptide; Brain natriuretic peptide; N terminal B type natriuretic peptide; N terminal pro brain natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN;

AORTA STENOSIS; BLOOD CHEMISTRY; CARDIOTOXICITY; CHEMOTHERAPY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DOWN REGULATION; DYSPNEA; ECHOCARDIOGRAPHY; EMERGENCY WARD; EVALUATION; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART TRANSPLANTATION; HEMODYNAMIC PARAMETERS; HEMODYNAMICS; HUMAN; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; SILENT MYOCARDIAL ISCHEMIA; SYSTOLIC HEART FAILURE;

BIOLOGICAL MARKERS; CORONARY DISEASE; DYSPNEA; EMERGENCY SERVICE, HOSPITAL; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 43949088518     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.10.018     Document Type: Review

References (118)

1. Maisel A. The coming of age of natriuretic peptides: the emperor does have clothes!. J Am Coll Cardiol 47 (2006) 61-64
2. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
3. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654
4. Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (2005) 948-954
5. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
6. Omland T., Persson A., Ng L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
7. Kucher N., Printzen G., Doernhoefer T., Windecker S., Meier B., and Hess O.M. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 107 (2003) 1576-1578
8. Kucher N., Printzen G., and Goldhaber S.Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 107 (2003) 2545-2547
9. Cowie M.R., Struthers A.D., Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350 (1997) 1349-1353
10. McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351 (1998) 9-13
11. Goetze J.P. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 50 (2004) 1503-1510
12. Luchner A., Stevens T.L., Borgeson D.D., et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274 (1998) H1684-H1689
13. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
14. Holmes S.J., Espiner E.A., Richards A.M., Yandle T.G., and Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 76 (1993) 91-96
15. Yoshimura M., Yasue H., Morita E., et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84 (1991) 1581-1588
16. Bettencourt P.M. Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives. Heart 91 (2005) 1489-1494
17. Goetze J.P., Jensen G., Moller S., Bendtsen F., Rehfeld J.F., and Henriksen J.H. BNP and N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Investig 36 (2006) 8-15
18. Tsutamoto T., Wada A., Sakai H., et al. Relationship between renal function and plasma brain natriuretic Peptide in patients with heart failure. J Am Coll Cardiol 47 (2006) 582-586
19. Wu A.H., Packer M., Smith A., et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 50 (2004) 867-873
20. Sykes E., Karcher R.E., Eisenstadt J., et al. Analytical relationships among Biosite, Bayer, and Roche methods for BNP and NT-proBNP. Am J Clin Pathol 123 (2005) 584-590
21. Hammerer-Lercher A., Ludwig W., Falkensammer G., et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem 50 (2004) 1174-1183
22. Wright S.P., Doughty R.N., Pearl A., et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 42 (2003) 1793-1800
23. Hobbs F.D., Davis R.C., Roalfe A.K., Hare R., Davies M.K., and Kenkre J.E. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 324 (2002) 1498
24. Zaphiriou A., Robb S., Murray-Thomas T., et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 7 (2005) 537-541
25. Latini R., Masson S., Wong M., et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 119 (2006) 70
26. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
27. Gardner R.S., Ozalp F., Murday A.J., Robb S.D., and McDonagh T.A. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24 (2003) 1735-1743
28. de Groote P., Dagorn J., Soudan B., Lamblin N., McFadden E., and Bauters C. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 43 (2004) 1584-1589
29. Ndrepepa G., Braun S., Niemoller K., et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation 112 (2005) 2102-2107
30. Kragelund C., Gronning B., Kober L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
31. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
32. Leuchte H.H., Baumgartner R.A., Nounou M.E., et al. Brain natriuretic Peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 173 (2006) 744-750
33. Williams M.H., Handler C.E., Akram R., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27 (2006) 1485-1494
34. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
35. Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., and Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. Jama 293 (2005) 1609-1616
36. Epshteyn V., Morrison K., Krishnaswamy P., et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26 (2003) 2081-2087
37. Bhalla M.A., Chiang A., Epshteyn V.A., et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 44 (2004) 1047-1052
38. Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., and Whooley M.A. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 108 (2003) 2987-2992
39. Foote R.S., Pearlman J.D., Siegel A.H., and Yeo K.T. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol 44 (2004) 1980-1987
40. Staub D., Jonas N., Zellweger M.J., et al. Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia. Am J Med 118 (2005) 1287
41. Staub D., Nusbaumer C., Zellweger M.J., et al. Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J 151 (2006) 1223-1230
42. Bergler-Klein J., Klaar U., Heger M., et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109 (2004) 2302-2308
43. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
44. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 109 (2004) 3176-3181
45. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. Jama 288 (2002) 1252-1259
46. Forfia P.R., Watkins S.P., Rame J.E., Stewart K.J., and Shapiro E.P. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 45 (2005) 1667-1671
47. Parsonage W.A., Galbraith A.J., Koerbin G.L., and Potter J.M. Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 95 (2005) 883-885
48. O'Neill J.O., Bott-Silverman C.E., McRae III A.T., et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J 149 (2005) 363-369
49. Nousiainen T., Vanninen E., Jantunen E., et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 251 (2002) 228-234
50. Sandri M.T., Salvatici M., Cardinale D., et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. Clin Chem 51 (2005) 1405-1410
51. Mehra M.R., Uber P.A., Potluri S., Ventura H.O., Scott R.L., and Park M.H. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 94 (2004) 454-458
52. Mehra M.R., Uber P.A., Walther D., et al. Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation: more than a hemodynamic marker. Circulation 114 1 Suppl (2006) I21-I26
53. Verma A., Kilicaslan F., Martin D.O., et al. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 92 (2006) 190-195
54. Manios E.G., Kallergis E.M., Kanoupakis E.M., et al. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators. Chest 128 (2005) 2604-2610
55. Aspromonte N., Ceci V., Chiera A., et al. Rapid brain natriuretic peptide test and Doppler echocardiography for early diagnosis of mild heart failure. Clin Chem 52 (2006) 1802-1808
56. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49 (2007) 1733-1739
57. Costello-Boerrigter L.C., Boerrigter G., Redfield M.M., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47 (2006) 345-353
58. Maisel A.S., Koon J., Krishnaswamy P., et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 141 (2001) 367-374
59. Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105 (2002) 595-601
60. Conen D., Zeller A., Pfisterer M., and Martina B. Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol 97 (2006) 249-252
61. Mueller T., Gegenhuber A., Dieplinger B., Poelz W., and Haltmayer M. Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem 51 (2005) 2245-2251
62. Mark P.B., Stewart G.A., Gansevoort R.T., et al. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant 21 (2006) 402-410
63. Mallamaci F., Zoccali C., Tripepi G., et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59 (2001) 1559-1566
64. Wolber T., Maeder M., Weilenmann D., et al. Integration of B-type natriuretic peptide levels with clinical data and exercise testing for predicting coronary artery disease. Am J Cardiol 98 (2006) 764-767
65. Galasko G.I., Lahiri A., Barnes S.C., Collinson P., and Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?. Eur Heart J 26 (2005) 2269-2276
66. Luchner A., Burnett Jr. J.C., Jougasaki M., et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 18 (2000) 1121-1128
67. Luchner A., Hengstenberg C., Lowel H., et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 39 (2002) 99-104
68. Tschope C., Kasner M., Westermann D., Gaub R., Poller W.C., and Schultheiss H.P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26 (2005) 2277-2284
69. Weber M., Dill T., Arnold R., et al. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 148 (2004) 612-620
70. Kragelund C, Gronning B, Omland T, et al. Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? Am Heart J 2006,151:712. e1-7.
71. Ng L.L., Loke I., Davies J.E., et al. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail 5 (2003) 775-782
72. Leuchte H.H., Neurohr C., Baumgartner R., et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 170 (2004) 360-365
73. Detaint D., Messika-Zeitoun D., Avierinos J.F., et al. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 111 (2005) 2391-2397
74. Sutton T.M., Stewart R.A., Gerber I.L., et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41 (2003) 2280-2287
75. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
76. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 (2006) 330-337
77. Cowie M.R., Jourdain P., Maisel A., et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24 (2003) 1710-1718
78. Silver M.A., Maisel A., Yancy C.W., et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10 5 Suppl 3 (2004) 1-30
79. Krishnaswamy P., Lubien E., Clopton P., et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 111 (2001) 274-279
80. Atisha D., Bhalla M.A., Morrison L.K., et al. A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction. Am Heart J 148 (2004) 518-523
81. Battaglia M., Pewsner D., Juni P., Egger M., Bucher H.C., and Bachmann L.M. Accuracy of B-type natriuretic Peptide tests to exclude congestive heart failure: systematic review of test accuracy studies. Arch Intern Med 166 (2006) 1073-1080
82. Vasan R.S., and Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 101 (2000) 2118-2121
83. Mottram P.M., Leano R., and Marwick T.H. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 92 (2003) 1434-1438
84. Persson H., Lonn E., Edner M., et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 49 (2007) 687-694
85. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007) 2539-50
86. Maisel A.S., McCord J., Nowak R.M., et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 41 (2003) 2010-2017
87. Anwaruddin S., Lloyd-Jones D.M., Baggish A., et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 47 (2006) 91-97
88. Luchner A., Hengstenberg C., Lowel H., Riegger G.A., Schunkert H., and Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 46 (2005) 118-123
89. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 (2004) 594-600
90. Mehra M.R., Uber P.A., Park M.H., et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43 (2004) 1590-1595
91. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31 (1998) 202-208
92. Christ-Crain M., Morgenthaler N.G., Meier C., et al. Pro-A-type and N-terminal pro-B-type natriuretic peptides in different thyroid function states. Swiss Med Wkly 135 (2005) 549-554
93. Willis M.S., Lee E.S., and Grenache D.G. Effect of anemia on plasma concentrations of NT-proBNP. Clin Chim Acta 358 (2005) 175-181
94. Graf K., Schaper C., Grafe M., Fleck E., and Kunkel G. Glucocorticoids and protein kinase C regulate neutral endopeptidase 24.11 in human vascular smooth muscle cells. Basic Res Cardiol 93 (1998) 11-17
95. Davis M.E., Richards A.M., Nicholls M.G., Yandle T.G., Frampton C.M., and Troughton R.W. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113 (2006) 977-985
96. Tang W.H., Girod J.P., Lee M.J., et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 108 (2003) 2964-2966
97. Logeart D., Thabut G., Jourdain P., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43 (2004) 635-641
98. Stanek B., Frey B., Hulsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 436-442
99. Yan R.T., White M., Yan A.T., et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 96 (2005) 698-704
100. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997) 509-516
101. Zugck C., Haunstetter A., Kruger C., et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 39 (2002) 1615-1622
102. Horwich T.B., Hamilton M.A., and Fonarow G.C. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 47 (2006) 85-90
103. Goetze J.P., Christoffersen C., Perko M., et al. Increased cardiac BNP expression associated with myocardial ischemia. Faseb J 17 (2003) 1105-1107
104. Richards A.M., Nicholls M.G., Yandle T.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 (1998) 1921-1929
105. Wu A.H., Smith A., Wieczorek S., et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92 (2003) 628-631
106. Schou M., Gustafsson F., Nielsen P.H., Madsen L.H., Kjaer A., and Hildebrandt P.R. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 9 (2007) 68-74
107. Brunner-La Rocca H.P., Buser P.T., Schindler R., Bernheim A., Rickenbacher P., and Pfisterer M. Management of elderly patients with congestive heart failure-design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 151 (2006) 949-955
108. Lainchbury J.G., Troughton R.W., Frampton C.M., et al. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 8 (2006) 532-538
109. De Sutter J., De Bacquer D., Cuypers S., et al. N-terminal pro-brain natriuretic peptide concentration predicts coronary events in men at work: a report from the BELSTRESS study. Eur Heart J 26 (2005) 2644-2649
110. Ma K.K., Ogawa T., and de Bold A.J. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 36 (2004) 505-513
111. Sahinarslan A., Cengel A., Okyay K., et al. B-type natriuretic peptide and extent of lesion on coronary angiography in stable coronary artery disease. Coron Artery Dis 16 (2005) 225-229
112. Ndrepepa G., Braun S., Mehilli J., et al. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol 95 (2005) 553-557
113. Bergeron S., Moller J.E., Bailey K.R., Chen H.H., Burnett J.C., and Pellikka P.A. Exertional changes in circulating cardiac natriuretic peptides in patients with suggested coronary artery disease. J Am Soc Echocardiogr 19 (2006) 772-776
114. Wolber T., Maeder M., Rickli H., et al. N-terminal pro-brain natriuretic peptide used for the prediction of coronary artery stenosis. Eur J Clin Invest 37 (2007) 18-25
115. Vanderheyden M., Goethals M., Verstreken S., et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 44 (2004) 2349-2354
116. Lim P., Monin J.L., Monchi M., et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 25 (2004) 2048-2053
117. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 (2002) 1623-1629
118. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7 (2001) 21-29